-In a phase III study, EGP-437 (EyeGate Pharma), a corticosteroid formulation, was found to match the response rate to prednisolone acetate 1%, the current standard of care for treatment of anterior uveitis.

	EGP-437 was administered in two iontophoretic treatments on two separate days, in contrast to prednisolone, which was administered as multiple daily eyedrops.

	Regarding safety, the incidence and severity of treatment-emergent adverse events in both groups were comparable and there were fewer incidences of elevated IOP in the EGP-437 group.

	“Inadequate compliance with aggressive eye drop regimens often leads to treatment failures,” said John Sheppard, MD, the studyÊ¼s principal investigator. “Offering our [patients with uveitis] a safe, effective treatment option that is controlled by the healthcare provider rather than the patient represents an important breakthrough.”

	“This is a major milestone for the company and the ophthalmology sector as it further validates a unique new way to deliver therapeutics into the eye,” said Stephen From, president and chief executive officer of EyeGate Pharma. “Treating uveitis requires up to 16 eyedrops per day over a period of 4 to 6 weeks, which is very inconvenient for the patient. A couple of treatments with our product produced the same results, which is much simpler and more reliable for the patient.”

News

EGP-437 (EyeGate Pharma), a corticosteroid formulation, was found to match the response rate to prednisolone acetate 1% for treatment of anterior uveitis.